Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2000-02-15
2001-12-11
Jones, W. Gary (Department: 1656)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C424S078050, C424S195110, C514S04400A, C514S469000
Reexamination Certificate
active
06329148
ABSTRACT:
BACKGROUND
The cellular growth of normal tissue is maintained in homeostasis. This balance is determined by cellular proliferation and renewal on one hand, and cell death on the other. Neoplasia can result from aberrant regulation of this homeostasis, through somatic genetic abnormalities that cause cancer initiation and progression. One approach to tumor therapy is to determine agents that act to initiate programmed cell death, or apoptosis. Apoptosis is a form of cell suicide that is critical for differentiation during embryogenesis and regulation of cell numbers. It can also be induced in neoplastic cells, so that they self-destruct. A growing body of evidence suggests that the intracellular “death program” activated during apoptosis is similar in different cell types and conserved during evolution.
Apoptosis involves two essential steps. The Bcl-2 family of proteins that consists of different anti- and pro-apoptotic members is important in the “decision” step of apoptosis. In contrast, the “execution” phase of apoptosis is mediated by the activation of caspases, cysteine proteases that induce cell death via the proteolytic cleavage of substrates vital for cellular homeostasis. Bcl-2-related proteins act upstream from caspases in the cell death pathway.
Tumor necrosis factor (TNF) is the prototypic member of a family of cytokines, which interact with their receptors to carry out diverse functions. Some TNF-receptor family members, termed the “death receptors”, which comprise a “death domain”, have the unique ability to transmit an intracellular death signal. These receptors include TNF-R1, Fas (CD95), TRAMP (wsl/Apo-3/DR-3), TRAIL-R1 (DR-4) and TRAIL-R2 (DR-5, TRICK2, KILLER). The ligands for these receptors are capable of inducing apoptosis in tumor cells. However, the potential utility of systemically administered TNF, Fas ligand or lymphotoxin has been limited by their acute toxic effects on normal tissues in vivo.
Progress in the treatment of solid tumors has been slow and sporadic. The efficacy of conventional chemotherapy in solid tumors is limited because tumors frequently have mutations in the p53 gene. Also, chemotherapy only kills rapidly dividing cells. Members of the tumor necrosis factor (TNF) family, however, induce apoptosis regardless of the p53 phenotype. Tumor necrosis factor-&agr; (TNF-&agr;), for example, shows broad cytotoxicity against many tumor cell lines but its clinical use is limited because it induces a profound inflammatory response through activation of NF-&kgr;B. Moreover, activation of NF-&kgr;B inhibits TNF-&agr;-induced apoptosis.
Many cancer cell lines are sensitive to the cytotoxic effects of TRAIL whereas most normal, non-transformed cells are resistant. Walczak et al. (1999)
Nature Medicine
5:157-163, fused the receptor-binding region of TRAIL to a leucine zipper motif that favors trimerization. Trimers of leucine zipper TRAIL efficiently killed cultured mammary adenocarcinoma cells but not normal, non-transformed mammary epithelial cells. Systemic administration was able to enhance survival of animals when challenged with this tumor cell line, without detectable adverse effects on viability, tissue integrity, or red and white blood cell counts. The tumoricidal effect of TRAIL was shown to be due to the rapid induction of tumor cell apoptosis.
Strategies to treat tumors with this family of proteins are of great interest. It may be possible to ‘sensitize’ resistant tumors to apoptosis, for example by modulating the expression or function of FLIP, which blocks the activity of caspases. Other strategies that have been suggested include manipulation of p53 expression. Methods of sensitization may permit the use of lower levels of the proteins, thereby reducing side effects. It may also permit the treatment of otherwise resistant tumors. Approximately 50% of the tumors tested have been resistant to killing by TRAIL (Griffith & Lynch (1998)
Curr. Opin. Immunol.
10:559-563).
Relevant Literature
A review of the TNF receptor superfamily may be found in Baker and Reddy (1998)
Oncogene
17(25): 3261-70. The tumor necrosis factor receptor (TNFR) superfamily represents a growing family, with over 20 members having been identified thus far in mammalian cells. These proteins share significant homologies in their extracellular ligand binding domains and intracellular effector (death) domains. Death signals seem to be associated with the activation of both the caspase and JUN kinase pathways. Gravestein and Borst (1998)
Semin Immunol
10(6): 423-34 also review this receptor superfamily. The use of TRAIL as an anti-tumor agent is discussed in Walczak et al. (1999)
Nature Medicine
5:157-163.
Yang et al. (1998)
Immunopharmacology
40(2): 139-49 provide evidence that suggests the immunosuppressive agent triptolide inhibits antigen or mitogen-induced T cell proliferation, and induces apoptotic death of T cell hybridomas and peripheral T cells. Shamon et al. (1997)
Cancer Lett
112(1): 113-7 evaluate the antitumor potential of triptolide.
The isolation, purification, and characterization of immunosuppressive compounds from tripterygium: triptolide and tripdiolide is reported by Gu et al. (1995)
Int J Immunopharmacol
17(5): 351-6.
SUMMARY OF THE INVENTION
Methods are provided for improved killing of tumor cells, by increasing the sensitivity of the cells to apoptosis induced by TNF family death domain ligands (DDL), e.g. TRAIL, TNF, Fas ligand, lymphotoxin, etc. The use of TRAIL or TNF is of particular interest. The tumor cells are contacted with diterpenoid triepoxides, e.g. triptolide, tripdiolide, etc., or prodrugs that convert to such compounds under physiological conditions, either locally or systemically. The killing of the tumor cells by induction of apoptosis through death domain ligands in greatly enhanced by the synergistic action of the diterpenoid and the DDL.
REFERENCES:
patent: 5759550 (1998-06-01), Wiedmann et al.
patent: 5994298 (1999-11-01), Tsai et al.
patent: wo9426265 (1994-11-01), None
patent: wo9731921 (1997-02-01), None
patent: 97/31921 (1997-09-01), None
patent: 98/52951 (1998-11-01), None
Shamon, Lisa A., et al., “Evaluation of the Mutagenic, Cytotoxic, and Antitumor Potential of Triptolide, a highly Oxygenated Diterpene Isolated from Tripterygium Wilfordii,” Cancer Letters (1997) vol. 112:113-117.*
Wiley, Steven R., et al., “Identification and Characterization of a New Member for the TNF Family that Induces Apoptosis,” Immunity (1995) vol. 3:673-682.*
Walczak, Hening et al., “Tumoricidal Activity of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand In Vivo,” Immunity (Feb. 1999) vol. 5(2): 157-163.*
Lee, K.Y et al., “PG490(Triptolide) Cooperates with Tumor Necrosis Factor to Induce Apoptosis in Tumor Cells,” Biological Chemistry, vol.274, No. 19, 1999 pp. 13451-13455.*
Lee et al, (May 7, 1999), “PG490 (Triptolide) Cooperates with Tumor Necrosis Factor-&agr; to Induce Apoptosis in Tumor Cells,”Journal of Biological Chemistry,vol. 274(19):13451-13455.
Keane et al. (Feb. 1, 1999), “Chemotherapy Augments TRAIL-Induced Apoptosis in Breast Cell Lines,”Cancer Research,vol. 59:734-741.
Snell et al. (1997), “Activity of TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Haematological Malignancies,”British Journal of Hematology,vol. 99:618-624.
Tengchaisri et al. (1998), “Antitumor Activity of Triptolide Against Cholangiocarcinoma Growth in vitro and in Hamsters,”Cancer Letters,vol. 133:169-175.
Baker, Stacey J., et al., “Modulation of Life and Death by the TNF Receptor Superfamily,”Oncogene(1998) vol. 17:3261-3270.
Fanslow, William C., et al., “Structural Characteristics of CD40 Ligand That Determine Biological Function,”Immunology(1994) vol. 6:267-278.
Gravestein, Loes A., et al., “Tumor Necrosis Factor Receptor Family Members in the Immune System,”Immunology(1998) vol. 10:423-434.
Griffith, Thomas S., et al., “TRAIL: a Molecule with Multiple Receptors and Control Mechanisms,”Current Opinion in Immunology(1998) vol. 10:559-563.
Gu, Wen-Zhen, et al., “Isolation, Purification, and Characterization of Immunosuppressive Compou
Kao Peter
Rosen Glenn D.
Bozicevic Field & Francis LLP
Ghashghaee Fariba
Jones W. Gary
Sherwood. Pamela J.
The Board of Trustees of the Leland Stanford University
LandOfFree
Combined therapy of diterpenoid triepoxides and death domain... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combined therapy of diterpenoid triepoxides and death domain..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combined therapy of diterpenoid triepoxides and death domain... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2571886